AMENDMENTS TO THE CLAIMS

The following listing of claims will replace all prior versions, and listings, of claims in the application.

Listing of claims:

1 (canceled).

2 (currently amended). ~~The method of claim 1, wherein said chronic pain is~~ A method for treating chronic pain selected from ~~neuropathic pain,~~ idiopathic pain, and pain associated with crush injury, constriction injury, burn pain, gout, trigeminal neuralgia, causalgia, plexus avulsion, limb amputation, chronic alcoholism, vitamin deficiency, uremia, or hypothyroidism, said method comprising administering to a subject in need of such treatment a composition comprising a MEK inhibitor selected from a compound of formula (I):



(I)

W is:



X is NH;

X_1 is O, or S;

X_2 is H, OH, SH, or NHR_E;

R_E is H or C_{1-4} alkyl;

each of R_1 and R_2 is independently selected from H, F, NO_2, Br and Cl; R_1 can also be $SO_2NR_GR_H$, or R_1 and R_2 together with the benzene ring to which they are attached constitute an indole, isoindole, benzofuran, benzothiophene, indazole, benzimidazole, or benzthioazole;

R_3 is H or F;

each of R_G, R_H, and R_4 is independently selected from H, Cl and CH_3;

and

wherein each hydrocarbon radical above is optionally substituted with between 1 and 3 substituents independently selected from halo, hydroxyl, amino, (amino)sulfonyl, and NO_2; and

wherein each heterocyclic radical above is optionally substituted with between 1 and 3 substituents independently selected from halo, C_{3-4} alkyl, C_{3-6} cycloalkyl, C_{3-4} alkenyl, C_{3-4} alkynyl, phenyl, hydroxyl, amino, (amino)sulfonyl, and NO_2, wherein each substituent alkyl, cycloalkyl, alkenyl, alkynyl or phenyl is in turn optionally substituted with between 1 and 2 substituents independently selected from halo, C_{1-2} alkyl, hydroxyl, amino, and NO_2;

or a pharmaceutically acceptable salt or C_{1-8} ester thereof.

3 and 4 (canceled).

5 (original). The method of claim 2, wherein said chronic pain is associated with chronic alcoholism, vitamin deficiency, uremia, or hypothyroidism.

6 (original). The method of claim 2, wherein said chronic pain is associated with idiopathic pain.

7-9 (canceled).

10 (currently amended). The method of ~~claim 1~~ claim 2, wherein R_1 is bromo or chloro.

11 (currently amended). A method of ~~claim 1~~ claim 2, wherein R_2 is fluoro.

12 (currently amended). A method of ~~claim 1~~ claim 2, wherein R_3 is H.

13 (original). A method of claim 12, wherein each of R_2 and R_3 is H.

14 (currently amended). A method of ~~claim 1~~ claim 2, wherein each of R_2 and R_3 is fluoro.

15 (original). A method of claim 14, wherein R_1 is bromo.

16 (original). A method of claim 14, wherein R_1 is fluoro.

17 (currently amended). A method of ~~claim 1~~ claim 2, wherein R_2 is nitro.

18 (original). A method of claim 16, wherein R_3 is H.

19 (currently amended). A method of ~~claim 1~~ claim 2, wherein R_4 is chloro.

20 (currently amended). A method of ~~claim 1~~ claim 2, wherein R_4 is methyl.

21-24 (canceled).

25 (currently amended). A method of ~~claim 1~~ claim 2, wherein X_2 is OH, SH, or NH_2.

26 (currently amended). A method of ~~claim 1~~ claim 2, wherein X_2 is $NHCH_3$ or OH.

27 (currently amended). A method of ~~claim 1~~ claim 2, wherein said MEK inhibitor ~~has a structure~~ is selected from: ~~[5-fluoro-2-(1H-tetrazol-5-yl)-phenyl]-(4-iodo-2-methyl-phenyl)-amine; [2,3-difluoro-6-(1H-tetrazol-5-yl)-phenyl]-(4-iodo-2-methyl-phenyl)-amine; (4-iodo-2-methyl-phenyl)-[2,3,4-trifluoro-6-(1H-tetrazol-5-yl)-phenyl]-amine; [4-bromo-2,3-difluoro-6-(1H-tetrazol-5-yl)-phenyl]-(4-iodo-2-methyl-phenyl)-amine; [5-fluoro-4-nitro-2-(1H-tetrazol-5-yl)-phenyl]-(4-iodo-2-methyl-phenyl)-amine; [2-(4,4-dimethyl-4,5-dihydro-oxazol-2-yl)-5-fluoro-phenyl]-(4-iodo-2-methyl-phenyl)-amine; [6-(4,4-dimethyl-4,5-dihydro-oxazol-2-yl)-2,3-difluoro-phenyl]-(4-iodo-2-methyl-phenyl)-amine; [6-(4,4-dimethyl-4,5-dihydro-oxazol-2-yl)-2,3,4-trifluoro-phenyl]-(4-iodo-2-methyl-phenyl)-amine;~~

~~[4-bromo-6-(4,4-dimethyl-4,5-dihydro-oxazol-2-yl)-2,3-difluoro-phenyl]-(4-iodo-2-methyl-phenyl)-amine; [2-(4,4-dimethyl-4,5-dihydro-oxazol-2-yl)-5-fluoro-4-nitro-phenyl]-(4-iodo-2-methyl-phenyl)-amine;~~ 5-[4-fluoro-2-(4-iodo-2-methyl-phenylamino)-phenyl]-[1,3,4]thiadiazol-2-ol; 5-[3,4-difluoro-2-(4-iodo-2-methyl-phenylamino)-phenyl]-[1,3,4]thiadiazol-2-ol; 5-[3,4,5-trifluoro-2-(4-iodo-2-methyl-phenylamino)-phenyl]-[1,3,4]thiadiazol-2-ol; 5-[5-bromo-3,4-difluoro-2-(4-iodo-2-methyl-phenylamino)-phenyl]-[1,3,4]thiadiazol-2-ol; 5-[4-fluoro-2-(4-iodo-2-methyl-phenylamino)-5-nitro-phenyl]-[1,3,4]thiadiazol-2-ol; 5-[4-fluoro-2-(4-iodo-2-methyl-phenylamino)-phenyl]-[1,3,4]oxadiazol-2-ol; 5-[3,4-difluoro-2-(4-iodo-2-methyl-phenylamino)-phenyl]-[1,3,4]oxadiazol-2-ol; 5-[3,4,5-trifluoro-2-(4-iodo-2-methyl-phenylamino)-phenyl]-[1,3,4]oxadiazol-2-ol; 5-[5-bromo-3,4-difluoro-2-(4-iodo-2-methyl-phenylamino)-phenyl]-[1,3,4]oxadiazol-2-ol; and 5-[4-fluoro-2-(4-iodo-2-methyl-phenylamino)-5-nitro-phenyl]-[1,3,4]oxadiazol-2-ol; ~~5-[4-fluoro-2-(4-iodo-2-methyl-phenylamino)-phenyl]-4H-[1,2,4]triazol-3-ol; 5-[3,4-difluoro-2-(4-iodo-2-methyl-phenylamino)-phenyl]-4H-[1,2,4]triazol-3-ol; 5-[3,4,5-trifluoro-2-(4-iodo-2-methyl-phenylamino)-phenyl]-4H-[1,2,4]triazol-3-ol; 5-[5-bromo-3,4-difluoro-2-(4-iodo-2-methyl-phenylamino)-phenyl]-4H-[1,2,4]triazol-3-ol; and 5-[4-fluoro-2-(4-iodo-2-methyl-phenylamino)-5-nitro-phenyl]-4H-[1,2,4]triazol-3-ol~~.

28 (currently amended). A method of ~~claim 1~~ claim 2, wherein said MEK inhibitor ~~has a structure~~ is selected from: 5-[4-fluoro-2-(4-iodo-2-methyl-phenylamino)-phenyl]-[1,3,4]thiadiazol-2-ylamine; 5-[3,4-Difluoro-2-(4-iodo-2-methyl-phenylamino)-phenyl]-[1,3,4]thiadiazol-2-ylamine; 5-[3,4,5-Trifluoro-2-(4-iodo-2-methyl-phenylamino)-phenyl]-[1,3,4]thiadiazol-2-ylamine; 5-[5-bromo-3,4-difluoro-2-(4-iodo-2-methyl-phenylamino)-phenyl]-[1,3,4]thiadiazol-2-ylamine; 5-[4-fluoro-2-(4-iodo-2-methyl-phenylamino)-5-nitro-phenyl]-[1,3,4]thiadiazol-2-ylamine; 5-[4-Fluoro-2-(4-iodo-2-methyl-phenylamino)-phenyl]-[1,3,4]oxadiazol-2-ylamine; 5-[3,4-difluoro-2-(4-iodo-2-methyl-phenylamino)-phenyl]-[1,3,4]oxadiazol-2-ylamine; 5-[3,4,5-trifluoro-2-(4-iodo-2-methyl-phenylamino)-phenyl]-[1,3,4]oxadiazol-2-ylamine; 5-[5-bromo-3,4-difluoro-2-(4-iodo-2-methyl-phenylamino)-phenyl]-[1,3,4]oxadiazol-2-ylamine; 5-[4-fluoro-2-(4-iodo-2-methyl-phenylamino)-5-nitro-phenyl]-[1,3,4]oxadiazol-2-ylamine; ~~5-[4-fluoro-2-(4-iodo-2-methyl-phenylamino)-phenyl]-4H-[1,2,4]triazol-3-ylamine; 5-[3,4-difluoro-2-(4-iodo-2-methyl-phenylamino)-phenyl]-4H-[1,2,4]triazol-3-ylamine; 5-[3,4,5-trifluoro-2-(4-iodo-2-methyl-phenylamino)-phenyl]-4H-[1,2,4]triazol-3-ylamine; 5-[5-bromo-3,4-difluoro-2-(4-iodo-2-methyl-phenylamino)-phenyl]-4H-[1,2,4]triazol-3-ylamine; 5-[4-fluoro-2-(4-iodo-2-methyl-phenylamino)-5-nitro-phenyl]-4H-[1,2,4]triazol-3-ylamine;~~ 5-[4-fluoro-2-(4-iodo-2-methyl-phenylamino)-phenyl]-

[1,3,4]thiadiazole-2-thiol; 5-[3,4-difluoro-2-(4-iodo-2-methyl-phenylamino)-phenyl]-[1,3,4]thiadiazole-2-thiol; 5-[3,4,5-trifluoro-2-(4-iodo-2-methyl-phenylamino)-phenyl]-[1,3,4]thiadiazole-2-thiol; 5-[5-bromo-3,4-difluoro-2-(4-iodo-2-methyl-phenylamino)-phenyl]-[1,3,4]thiadiazole-2-thiol; 5-[4-fluoro-2-(4-iodo-2-methyl-phenylamino)-5-nitro-phenyl]-[1,3,4]thiadiazole-2-thiol; 5-[4-fluoro-2-(4-iodo-2-methyl-phenylamino)-phenyl]-[1,3,4]oxadiazole-2-thiol; 5-[3,4-difluoro-2-(4-iodo-2-methyl-phenylamino)-phenyl]-[1,3,4]oxadiazole-2-thiol; 5-[3,4,5-trifluoro-2-(4-iodo-2-methyl-phenylamino)-phenyl]-[1,3,4]oxadiazole-2-thiol; 5-[5-bromo-3,4-difluoro-2-(4-iodo-2-methyl-phenylamino)-phenyl]-[1,3,4]oxadiazole-2-thiol; and 5-[4-fluoro-2-(4-iodo-2-methyl-phenylamino)-5-nitro-phenyl]-[1,3,4]oxadiazole-2-thiol; ~~5-[4-fluoro-2-(4-iodo-2-methyl-phenylamino)-phenyl]-4H-[1,2,4]triazole-3-thiol; 5-[3,4-difluoro-2-(4-iodo-2-methyl-phenylamino)-phenyl]-4H-[1,2,4]triazole-3-thiol; 5-[3,4,5-trifluoro-2-(4-iodo-2-methyl-phenylamino)-phenyl]-4H-[1,2,4]triazole-3-thiol; 5-[5-bromo-3,4-difluoro-2-(4-iodo-2-methyl-phenylamino)-phenyl]-4H-[1,2,4]triazole-3-thiol; and 5-[4-fluoro-2-(4-iodo-2-methyl-phenylamino)-5-nitro-phenyl]-4H-[1,2,4]triazole-3-thiol~~.

~~29~~-31 (canceled).

32 (currently amended). A method of ~~claim 1~~ claim 2, wherein said MEK inhibitor ~~has a structure~~ is selected from: ~~2,4-bis-(2-chloro-4-iodo-phenylamino)-3fluoro5-nitro-benzoic acid;~~ 5-[3,4difluoro-2-(4-iodo-2-methyl-phenylamino)-phenyl]-[1,3,4]oxadiazol-2-ylamine; 5-[4-fluoro-2-(4-iodo-2-methyl-phenylamino)-phenyl]-[1,3,4]oxadiazol-2-ol; (2,3-difluoro-6-[1,3,4]oxadiazol-2-yl-phenyl)(-(4-iodo-2-methyl-phenyl)-amine; and 5-[3,4-difluoro-2-(4-iodo-2-methyl-phenylamino)-phenyl]-[1,3,4]oxadiazole-2-thiol; ~~5-[3,4difluoro-2-(4-iodo-2-methyl-phenylamino)-phenyl]-4*H*-[1,2,4]triazole-3-ylamine; and 5-[3,4-difluoro-2-(4-iodo-2-methyl-phenylamino)-phenyl]-4*H*-[1,2,4]triazole-3-thiol~~.

33 (canceled).

34 (new). The method of claim 2, wherein the chronic pain is associated with crush injury or constriction injury.

35 (new). The method of claim 2, wherein the chronic pain is associated with burn pain, gout, trigeminal neuralgia, causalgia, plexus avulsion, or limb amputation.